ISRCTN57388990已完成2 期
Florbetapir F18 (18F-AV-45) amyloid PET imaging in focal dementia syndromes
Avid Radiopharmaceuticals Inc. (USA)0 个研究点目标入组 25 人开始时间: 2011年11月8日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Are currently enrolled in the longitudinal study of frontotemporal lobular degeneration at the Dementia Research Centre (DRC) at University College London (UCL)
- •2. Patients with PPA will have undergone detailed neuropsychological assessments and will be classified in one of three syndromic groups: PNFA, LPA, or SD
- •3. Can tolerate a PET scan procedure
- •PCA-AD Group
- •1. 1.Are currently enrolled in the longitudinal study of posterior cortical atrophy at the Dementia Research Centre (DRC)
- •2. Patients with PCA-AD will have undergone detailed neurological assessments and will fulfil the following criteria:
- •2.1. Insidious onset of cognitive decline, sufficient to interfere with activities of daily living, with absence of structural lesion or significant whilte matter disease on magnetic resonnace imaging (MRI)
- •2.2. Relatively preserved episodic memory; deficits on standard psychological testing in at least two of four posterior cortical functions:
- •2.2.1. Object perception
- •2.2.2. Space perception
- •2.2.3. Calculation
- •2.2.4. Spelling
- •3. Can tolerate a PET scan procedure
- •Cognitively normal group
- •1. Have no cognition complaints
- •2. Are between 55 and 90 years of age
- •3. Give informed consent
- •4. Can tolerate a PET scan procedure
- •Participants may be male or female.
- •Subjects in the cognitively normal group must be aged 55 ?- 90 years.
- •Female subjects in the PPA and PCA-AD groups must be over 55 years and not have child bearing potential; male subjects may be younger.
排除标准
- •1. Have clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances
- •2. Have a clinically significant cardiovascular disease
- •3. Have a clinically significant infectious disease
- •4. Have a history of alcohol or substance abuse or dependence
- •5. Have a history of severe drug allergy or hypersensitivity
- •6. Women of child bearing potential
研究者
相似试验
进行中（未招募）
1 期
oneFocal dementia syndromes - primary aphasiaMedDRA version: 14.1 Level: LLT Classification code 10012292 Term: Dementia of the Alzheimer's type NOS System Organ Class: 10029205 - Nervous system disordersEUCTR2010-023852-10-GBAvid Radiopharmaceuticals, Inc.23
已完成
3 期
Cerebral Amyloid Imaging Using Florbetapir (AV-45)Cognition DisordersDementiaNCT02813434Centre Hospitalier Universitaire, Amiens92
已完成
不适用
18F flutemetamol amyloid-beta PET imaging compared with 11CPIB across the spectrum of Alzheimer's diseaseAlzheimer's diseaseJPRN-UMIN000019573Shonan-Atsugi hospital200
已完成
不适用
Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission TomographyMultiple MyelomaNCT03779815Ulsan University Hospital14
已完成
Unknown
[18F]-flutemetamol amyloid imaging along the continuum from normal cognitive status to Alzheimer's disease dementia.JPRN-jRCT1091220124Shizuo Hatashita120